http://hl7.org/fhir/uv/ebm/Citation/179631
type: Citation
node role: treeRoot
id:
  v: 179631
meta:
  version id:
    v: 21
  last updated:
    v: 2025-10-13T12:34:35.118Z
  profile:
    v: http://hl7.org/fhir/uv/ebm/StructureDefinition/journal-article-citation
    l: journal-article-citation
language:
  v: en
text:
  status:
    v: extensions
  div:
    v: Generated Narrative: Citation 179631 version: 21; Last updated: 2025-10-13 12:34:35+0000; Language: en Profile: JournalArticleCitation ArtifactPublicationStatus: Active url: https://fevir.net/resources/Citation/179631 identifier: FEvIR Object Identifier/179631, https://pubmed.ncbi.nlm.nih.gov/19029421 title: 19029421 Phase III trial of androgen ablation with or without three cycles of systemic chemotherapy for advanced prostate cancer. status: Active author: Computable Publishing®: MEDLINE-to-FEvIR Converter: publisher: Computable Publishing LLC contact: support@computablepublishing.com description: This Citation Resource is referenced in an example for the EBMonFHIR Implementation Guide. UseContexts - Code Value[x] * Citation Classification Type: fevir-platform-use (FEvIR Platform Use) Medline Base copyright: https://creativecommons.org/licenses/by-nc-sa/4.0/ approvalDate: 2009-01-13 lastReviewDate: 2023-02-02 classification type: Citation Source classifier: MEDLINE classification type: MEDLINE Citation Owner classifier: National Library of Medicine, Index Section currentState: Medline Citation Status of Medline, PubMed PublicationStatus of ppublish statusDate activity: PubMed Pubstatus of Pubmed period: ?? --> 2008-11-26 09:00:00+0000 statusDate activity: PubMed Pubstatus of Medline period: ?? --> 2009-01-14 09:00:00+0000 statusDate activity: PubMed Pubstatus of Entrez period: ?? --> 2008-11-26 09:00:00+0000 statusDate activity: PubMed Pubstatus of PMC release period: ?? --> 2009-12-20 citedArtifact identifier: https://pubmed.ncbi.nlm.nih.gov/19029421, https://www.ncbi.nlm.nih.gov/pmc//PMC3864402, https://doi.org/10.1200/JCO.2007.15.9830, pii/JCO.2007.15.9830 Titles - Type Text * Primary title Phase III trial of androgen ablation with or without three cycles of systemic chemotherapy for advanced prostate cancer. Abstracts - Type Text * Primary human use PURPOSE: We conducted a phase III trial in patients with previously untreated metastatic prostate cancer to test…
contained: Practitioner
  id:
    v: contributor0
  name:
    family:
      v: Millikan
    given:
      v: Randall E
contained: Practitioner
  id:
    v: contributor1
  name:
    family:
      v: Wen
    given:
      v: Sijin
contained: Practitioner
  id:
    v: contributor2
  name:
    family:
      v: Pagliaro
    given:
      v: Lance C
contained: Practitioner
  id:
    v: contributor3
  name:
    family:
      v: Brown
    given:
      v: Melissa A
contained: Practitioner
  id:
    v: contributor4
  name:
    family:
      v: Moomey
    given:
      v: Brenda
contained: Practitioner
  id:
    v: contributor5
  name:
    family:
      v: Do
    given:
      v: Kim-Anh
contained: Practitioner
  id:
    v: contributor6
  name:
    family:
      v: Logothetis
    given:
      v: Christopher J
contained: ArtifactAssessment
  id:
    v: meshHeading0
  artifact: Reference
    l: #
    reference:
      v: #
    type:
      v: Citation
      l: Citation
  content:
    type:
      text:
        v: components (if present) include qualifier codings
    classifier:
      coding: D000328
    free to share:
      v: true
  content:
    type:
      text:
        v: components (if present) include qualifier codings
    classifier:
      coding: D000368
    free to share:
      v: true
  content:
    type:
      text:
        v: components (if present) include qualifier codings
    classifier:
      coding: D000369
    free to share:
      v: true
  content:
    type:
      text:
        v: components (if present) include qualifier codings
    classifier:
      coding: D000726
    free to share:
      v: true
    component:
      classifier:
        coding: Q000627
  content:
    type:
      text:
        v: components (if present) include qualifier codings
    classifier:
      coding: D000903
    free to share:
      v: true
    component:
      classifier:
        coding: Q000008
  content:
    type:
      text:
        v: components (if present) include qualifier codings
    classifier:
      coding: D018906
    free to share:
      v: true
    component:
      classifier:
        coding: Q000008
  content:
    type:
      text:
        v: components (if present) include qualifier codings
    classifier:
      coding: D000972
    free to share:
      v: true
    component:
      classifier:
        coding: Q000008
  content:
    type:
      text:
        v: components (if present) include qualifier codings
    classifier:
      coding: D000971
    free to share:
      v: true
    component:
      classifier:
        coding: Q000627
  content:
    type:
      text:
        v: components (if present) include qualifier codings
    classifier:
      coding: D004317
    free to share:
      v: true
    component:
      classifier:
        coding: Q000008
  content:
    type:
      text:
        v: components (if present) include qualifier codings
    classifier:
      coding: D004961
    free to share:
      v: true
    component:
      classifier:
        coding: Q000008
  content:
    type:
      text:
        v: components (if present) include qualifier codings
    classifier:
      coding: D006801
    free to share:
      v: true
  content:
    type:
      text:
        v: components (if present) include qualifier codings
    classifier:
      coding: D007654
    free to share:
      v: true

v: mesh-heading

v: MeSH heading

v: D000328

v: Adult

v: false

v: qualifier

v: is not a major topic

v: mesh-heading

v: MeSH heading

v: D000368

v: Aged

v: false

v: qualifier

v: is not a major topic

v: mesh-heading

v: MeSH heading

v: D000369

v: Aged, 80 and over

v: false

v: qualifier

v: is not a major topic

v: mesh-heading

v: MeSH heading

v: D000726

v: Androgen Antagonists

v: false

v: qualifier

v: is not a major topic

v: qualifier

Q000627
system:
  v: https://www.nlm.nih.gov/mesh
  l: mesh
code:
  v: Q000627
display:
  v: therapeutic use

text:
  v: is Major topic

coding:
  system:
    v: http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl
    l: Thesaurus.owl
  code:
    v: C49488
  display:
    v: Yes

v: mesh-heading

v: MeSH heading

v: D000903

v: Antibiotics, Antineoplastic

v: false

v: qualifier

v: is not a major topic

v: qualifier

Q000008
system:
  v: https://www.nlm.nih.gov/mesh
  l: mesh
code:
  v: Q000008
display:
  v: administration & dosage

text:
  v: is Major topic

coding:
  system:
    v: http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl
    l: Thesaurus.owl
  code:
    v: C49487
  display:
    v: No

v: mesh-heading

v: MeSH heading

v: D018906

v: Antineoplastic Agents, Alkylating

v: false

v: qualifier

v: is not a major topic

v: qualifier

Q000008
system:
  v: https://www.nlm.nih.gov/mesh
  l: mesh
code:
  v: Q000008
display:
  v: administration & dosage

text:
  v: is Major topic

coding:
  system:
    v: http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl
    l: Thesaurus.owl
  code:
    v: C49487
  display:
    v: No

v: mesh-heading

v: MeSH heading

v: D000972

v: Antineoplastic Agents, Phytogenic

v: false

v: qualifier

v: is not a major topic

v: qualifier

Q000008
system:
  v: https://www.nlm.nih.gov/mesh
  l: mesh
code:
  v: Q000008
display:
  v: administration & dosage

text:
  v: is Major topic

coding:
  system:
    v: http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl
    l: Thesaurus.owl
  code:
    v: C49487
  display:
    v: No

v: mesh-heading

v: MeSH heading

v: D000971

v: Antineoplastic Combined Chemotherapy Protocols

v: false

v: qualifier

v: is not a major topic

v: qualifier

Q000627
system:
  v: https://www.nlm.nih.gov/mesh
  l: mesh
code:
  v: Q000627
display:
  v: therapeutic use

text:
  v: is Major topic

coding:
  system:
    v: http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl
    l: Thesaurus.owl
  code:
    v: C49488
  display:
    v: Yes

v: mesh-heading

v: MeSH heading

v: D004317

v: Doxorubicin

v: false

v: qualifier

v: is not a major topic

v: qualifier

Q000008
system:
  v: https://www.nlm.nih.gov/mesh
  l: mesh
code:
  v: Q000008
display:
  v: administration & dosage

text:
  v: is Major topic

coding:
  system:
    v: http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl
    l: Thesaurus.owl
  code:
    v: C49487
  display:
    v: No

v: mesh-heading

v: MeSH heading

v: D004961

v: Estramustine

v: false

v: qualifier

v: is not a major topic

v: qualifier

Q000008
system:
  v: https://www.nlm.nih.gov/mesh
  l: mesh
code:
  v: Q000008
display:
  v: administration & dosage

text:
  v: is Major topic

coding:
  system:
    v: http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl
    l: Thesaurus.owl
  code:
    v: C49487
  display:
    v: No

v: mesh-heading

v: MeSH heading

v: D006801

v: Humans

v: false

v: qualifier

v: is not a major topic

v: mesh-heading

v: MeSH heading

v: D007654

v: Ketoconazole

v: false

type:
  text:
    v: qualifier
classifier:
  text:
    v: is not a major topic

type:
  text:
    v: qualifier
classifier:
  coding: Q000008
    system:
      v: https://www.nlm.nih.gov/mesh
      l: mesh
    code:
      v: Q000008
    display:
      v: administration & dosage
component:
  type:
    text:
      v: is Major topic
  classifier:
    coding:
      system:
        v: http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl
        l: Thesaurus.owl
      code:
        v: C49487
      display:
        v: No

type:
  coding:
    system:
      v: http://terminology.hl7.org/CodeSystem/cited-artifact-classification-type
      l: cited-artifact-classification-type
    code:
      v: mesh-heading
    display:
      v: MeSH heading
  text:
    v: components (if present) include qualifier codings
classifier:
  coding: D008297
    system:
      v: https://www.nlm.nih.gov/mesh
      l: mesh
    code:
      v: D008297
    display:
      v: Male
    user selected:
      v: false
free to share:
  v: true
component:
  type:
    text:
      v: qualifier
  classifier:
    text:
      v: is not a major topic

type:
  coding:
    system:
      v: http://terminology.hl7.org/CodeSystem/cited-artifact-classification-type
      l: cited-artifact-classification-type
    code:
      v: mesh-heading
    display:
      v: MeSH heading
  text:
    v: components (if present) include qualifier codings
classifier:
  coding: D008875
    system:
      v: https://www.nlm.nih.gov/mesh
      l: mesh
    code:
      v: D008875
    display:
      v: Middle Aged
    user selected:
      v: false
free to share:
  v: true
component:
  type:
    text:
      v: qualifier
  classifier:
    text:
      v: is not a major topic

type:
  coding:
    system:
      v: http://terminology.hl7.org/CodeSystem/cited-artifact-classification-type
      l: cited-artifact-classification-type
    code:
      v: mesh-heading
    display:
      v: MeSH heading
  text:
    v: components (if present) include qualifier codings
classifier:
  coding: D009362
    system:
      v: https://www.nlm.nih.gov/mesh
      l: mesh
    code:
      v: D009362
    display:
      v: Neoplasm Metastasis
    user selected:
      v: false
free to share:
  v: true
component:
  type:
    text:
      v: qualifier
  classifier:
    text:
      v: is not a major topic

type:
  coding:
    system:
      v: http://terminology.hl7.org/CodeSystem/cited-artifact-classification-type
      l: cited-artifact-classification-type
    code:
      v: mesh-heading
    display:
      v: MeSH heading
  text:
    v: components (if present) include qualifier codings
classifier:
  coding: D011471
    system:
      v: https://www.nlm.nih.gov/mesh
      l: mesh
    code:
      v: D011471
    display:
      v: Prostatic Neoplasms
    user selected:
      v: false
free to share:
  v: true
component:
  type:
    text:
      v: qualifier
  classifier:
    text:
      v: is not a major topic
component:
  type:
    text:
      v: qualifier
  classifier:
    coding: Q000188
      system:
        v: https://www.nlm.nih.gov/mesh
        l: mesh
      code:
        v: Q000188
      display:
        v: drug therapy
  component:
    type:
      text:
        v: is Major topic
component:
  type:
    text:
      v: qualifier
  classifier:
    coding: Q000401
      system:
        v: https://www.nlm.nih.gov/mesh
        l: mesh
      code:
        v: Q000401
      display:
        v: mortality
  component:
    type:
      text:
        v: is Major topic

v: C49488

v: Yes

v: C49487

v: No

type:
  coding:
    system:
      v: http://terminology.hl7.org/CodeSystem/cited-artifact-classification-type
      l: cited-artifact-classification-type
    code:
      v: mesh-heading
    display:
      v: MeSH heading
  text:
    v: components (if present) include qualifier codings
classifier:
  coding: D014747
    system:
      v: https://www.nlm.nih.gov/mesh
      l: mesh
    code:
      v: D014747
    display:
      v: Vinblastine
    user selected:
      v: false
free to share:
  v: true
component:
  type:
    text:
      v: qualifier
  classifier:
    text:
      v: is not a major topic
component:
  type:
    text:
      v: qualifier
  classifier:
    coding: Q000008
      system:
        v: https://www.nlm.nih.gov/mesh
        l: mesh
      code:
        v: Q000008
      display:
        v: administration & dosage
  component:
    type:
      text:
        v: is Major topic

v: C49487

v: No

url:
  v: http://hl7.org/fhir/uv/ebm/StructureDefinition/artifact-publication-status
  l: artifact-publication-status
value: CodeableConcept
  coding:
    system:
      v: http://terminology.hl7.org/CodeSystem/cited-artifact-status-type
      l: cited-artifact-status-type
    code:
      v: active
    display:
      v: Active

type:
  coding:
    system:
      v: http://terminology.hl7.org/CodeSystem/v2-0203
      l: v2-0203
    code:
      v: ACSN
    display:
      v: Accession ID
  text:
    v: FEvIR Object Identifier
system:
  v: https://fevir.net/FOI
  l: FOI
value:
  v: 179631
assigner:
  display:
    v: Computable Publishing LLC

system:
  v: https://pubmed.ncbi.nlm.nih.gov
  l: pubmed.ncbi.nlm.nih.gov
value:
  v: 19029421

v: 19029421 Phase III trial of androgen ablation with or without three cycles of systemic chemotherapy for advanced prostate cancer.

v: active

name:
  v: Computable Publishing®: MEDLINE-to-FEvIR Converter

v: Computable Publishing LLC

telecom:
  system:
    v: email

v: This Citation Resource is referenced in an example for the EBMonFHIR Implementation Guide.

code:
  system:
    v: http://terminology.hl7.org/CodeSystem/citation-classification-type
    l: citation-classification-type
  code:
    v: fevir-platform-use
  display:
    v: FEvIR Platform Use
value: CodeableConcept
  coding:
    system:
      v: http://terminology.hl7.org/CodeSystem/citation-artifact-classifier
      l: citation-artifact-classifier
    code:
      v: medline-base
    display:
      v: Medline Base
    user selected:
      v: false

v: 2009-01-13

v: 2023-02-02

type:
  coding:
    system:
      v: http://terminology.hl7.org/CodeSystem/citation-classification-type
      l: citation-classification-type
    code:
      v: citation-source
    display:
      v: Citation Source
classifier:
  text:
    v: MEDLINE

type:
  coding:
    system:
      v: http://terminology.hl7.org/CodeSystem/citation-classification-type
      l: citation-classification-type
    code:
      v: medline-owner
    display:
      v: MEDLINE Citation Owner
classifier:
  coding:
    system:
      v: https://www.nlm.nih.gov/bsd/licensee/elements_descriptions.html#owner_value
      l: owner value
    code:
      v: NLM
    display:
      v: National Library of Medicine, Index Section
    user selected:
      v: false

coding:
  system:
    v: http://hl7.org/fhir/citation-status-type
    l: citation-status-type
  code:
    v: medline-medline
  display:
    v: Medline Citation Status of Medline

coding:
  system:
    v: http://hl7.org/fhir/citation-status-type
    l: citation-status-type
  code:
    v: pubmed-publication-status-ppublish
  display:
    v: PubMed PublicationStatus of ppublish

activity:
  coding:
    system:
      v: http://hl7.org/fhir/citation-status-type
      l: citation-status-type
    code:
      v: pubmed-pubstatus-pubmed
    display:
      v: PubMed Pubstatus of Pubmed
period:
  end:
    v: 2008-11-26T09:00:00.000Z

activity:
  coding:
    system:
      v: http://hl7.org/fhir/citation-status-type
      l: citation-status-type
    code:
      v: pubmed-pubstatus-medline
    display:
      v: PubMed Pubstatus of Medline
period:
  end:
    v: 2009-01-14T09:00:00.000Z

activity:
  coding:
    system:
      v: http://hl7.org/fhir/citation-status-type
      l: citation-status-type
    code:
      v: pubmed-pubstatus-entrez
    display:
      v: PubMed Pubstatus of Entrez
period:
  end:
    v: 2008-11-26T09:00:00.000Z

activity:
  coding:
    system:
      v: http://hl7.org/fhir/citation-status-type
      l: citation-status-type
    code:
      v: pubmed-pubstatus-pmc-release
    display:
      v: PubMed Pubstatus of PMC release
period:
  end:
    v: 2009-12-20

identifier:
  system:
    v: https://pubmed.ncbi.nlm.nih.gov
    l: pubmed.ncbi.nlm.nih.gov
  value:
    v: 19029421
identifier:
  system:
    v: https://www.ncbi.nlm.nih.gov/pmc/
    l: pmc
  value:
    v: PMC3864402
identifier:
  system:
    v: https://doi.org
    l: doi.org
  value:
    v: 10.1200/JCO.2007.15.9830
identifier:
  type:
    coding:
      system:
        v: http://terminology.hl7.org/CodeSystem/v2-0203
        l: v2-0203
      code:
        v: ACSN
      display:
        v: Accession ID
    text:
      v: pii
  value:
    v: JCO.2007.15.9830
title:
  type:
    coding:
      system:
        v: http://terminology.hl7.org/CodeSystem/title-type
        l: title-type
      code:
        v: primary
      display:
        v: Primary title
  text:
    v: Phase III trial of androgen ablation with or without three cycles of systemic chemotherapy for advanced prostate cancer.
abstract:
  type:
    coding:
      system:
        v: http://terminology.hl7.org/CodeSystem/cited-artifact-abstract-type
        l: cited-artifact-abstract-type
      code:
        v: primary-human-use
      display:
        v: Primary human use
  text:
    v: **PURPOSE:** We conducted a phase III trial in patients with previously untreated metastatic prostate cancer to test the hypothesis that three 8-week cycles of ketoconazole and doxorubicin alternating with vinblastine and estramustine, given in addition to standard androgen deprivation, would delay the appearance of castrate-resistant disease. **PATIENTS AND METHODS:** Eligible patients had metastatic prostate cancer threatening enough to justify sustained androgen ablation and were fit enough for chemotherapy. The primary end point was time to castrate-resistant progression as shown by increasing prostate-specific antigen, new radiographic lesions, worsening cancer-related symptoms, or receipt of any other systemic therapy. **RESULTS:** Three hundred six patients were registered; 286 are reported. Median time to progression was 24 months (95% CI, 18 to 39 months) in the standard therapy arm, and 35 months (95% CI, 26 to 44 months) in the chemohormonal group (P = .39). At median follow-up of 6.4 years, overall survival was 5.4 years (95% CI, 4.7 to 7.8 years) in the standard therapy arm versus 6.1 years (95% CI, 5.1 to 10.1 years; P = .41). Prostate-specific antigen kinetics at the time of androgen ablation and the nadir after hormone treatment were strongly correlated with survival. Chemotherapy significantly increased the burden of therapy, with 51% of patients experiencing an adverse event of grade 3 or worse, especially thromboembolic events. **CONCLUSION:** There is no role for ketoconazole and doxorubicin alternating with vinblastine and estramustine before emergence of a castrate-resistant phenotype.
relates to:
  type:
    v: cites
  classifier:
    coding:
      system:
        v: http://hl7.org/fhir/citation-artifact-classifier
        l: citation-artifact-classifier
      code:
        v: D016428
      display:
        v: Journal Article
  citation:
    v: Jemal A, Siegel R, Ward E, et al: Cancer Statistics, 2007. CA Cancer J Clin 57:43-66, 2007
  target: Reference
    l: https://pubmed.ncbi.nlm.nih.gov/17237035/
    reference:
      v: https://pubmed.ncbi.nlm.nih.gov/17237035/
    type:
      v: Citation
      l: Citation
    identifier:
      system:
        v: https://pubmed.ncbi.nlm.nih.gov
        l: pubmed.ncbi.nlm.nih.gov
      value:
        v: 17237035
relates to:
  type:
    v: cites
  classifier:
    coding:
      system:
        v: http://hl7.org/fhir/citation-artifact-classifier
        l: citation-artifact-classifier
      code:
        v: D016428
      display:
        v: Journal Article
  citation:
    v: Yagoda A, Petrylak D: Cytotoxic chemotherapy for advanced hormone-resistant prostate cancer. Cancer 71:1098-1109, 1993
  target: Reference
    l: https://pubmed.ncbi.nlm.nih.gov/7679039/
    reference:
      v: https://pubmed.ncbi.nlm.nih.gov/7679039/
    type:
      v: Citation
      l: Citation
    identifier:
      system:
        v: https://pubmed.ncbi.nlm.nih.gov
        l: pubmed.ncbi.nlm.nih.gov
      value:
        v: 7679039
relates to:
  type:
    v: cites
  classifier:
    coding:
      system:
        v: http://hl7.org/fhir/citation-artifact-classifier
        l: citation-artifact-classifier
      code:
        v: D016428
      display:
        v: Journal Article
  citation:
    v: Beer T, Raghavan D: Chemotherapy for hormone-refractory prostate cancer: Beauty is in the eye of the beholder. Prostate 45:184-193, 2000
  target: Reference
    l: https://pubmed.ncbi.nlm.nih.gov/11027418/
    reference:
      v: https://pubmed.ncbi.nlm.nih.gov/11027418/
    type:
      v: Citation
      l: Citation
    identifier:
      system:
        v: https://pubmed.ncbi.nlm.nih.gov
        l: pubmed.ncbi.nlm.nih.gov
      value:
        v: 11027418
relates to:
  type:
    v: cites
  classifier:
    coding:
      system:
        v: http://hl7.org/fhir/citation-artifact-classifier
        l: citation-artifact-classifier
      code:
        v: D016428
      display:
        v: Journal Article
  citation:
    v: Ellerhorst JA, Tu SM, Amato RJ, et al: Phase II trial of alternating weekly chemohormonal therapy for patients with androgen-independent prostate cancer. Clin Cancer Res 3:2371-2376, 1997
  target: Reference
    l: https://pubmed.ncbi.nlm.nih.gov/9815636/
    reference:
      v: https://pubmed.ncbi.nlm.nih.gov/9815636/
    type:
      v: Citation
      l: Citation
    identifier:
      system:
        v: https://pubmed.ncbi.nlm.nih.gov
        l: pubmed.ncbi.nlm.nih.gov
      value:
        v: 9815636
relates to:
  type:
    v: cites
  classifier:
    coding:
      system:
        v: http://hl7.org/fhir/citation-artifact-classifier
        l: citation-artifact-classifier
      code:
        v: D016428
      display:
        v: Journal Article
  citation:
    v: Smith DC, Esper P, Strawderman M, et al: Phase II trial of oral estramustine, oral etoposide, and intravenous paclitaxel in hormone-refractory prostate cancer. J Clin Oncol 17:1664-1671, 1999
  target: Reference
    l: https://pubmed.ncbi.nlm.nih.gov/10561202/
    reference:
      v: https://pubmed.ncbi.nlm.nih.gov/10561202/
    type:
      v: Citation
      l: Citation
    identifier:
      system:
        v: https://pubmed.ncbi.nlm.nih.gov
        l: pubmed.ncbi.nlm.nih.gov
      value:
        v: 10561202
relates to:
  type:
    v: cites
  classifier:
    coding:
      system:
        v: http://hl7.org/fhir/citation-artifact-classifier
        l: citation-artifact-classifier
      code:
        v: D016428
      display:
        v: Journal Article
  target: Reference

v: NLM

v: NLM

v: NLM

v: NLM

v: NLM

v: Kelly WK, Curley T, Slovin S, et al: Paclitaxel, estramustine phosphate, and carboplatin in patients with advanced prostate cancer. J Clin Oncol 19:44-53, 2001

Reference
l: https://pubmed.ncbi.nlm.nih.gov/11134194/
reference:
  v: https://pubmed.ncbi.nlm.nih.gov/11134194/
type:
  v: Citation
  l: Citation
identifier:
  system:
    v: https://pubmed.ncbi.nlm.nih.gov
    l: pubmed.ncbi.nlm.nih.gov
  value:
    v: 11134194
  assigner:
    display:
      v: NLM

type:
  v: cites
classifier:
  coding:
    system:
      v: http://hl7.org/fhir/citation-artifact-classifier
      l: citation-artifact-classifier
    code:
      v: D016428
    display:
      v: Journal Article
citation:
  v: Millikan RE, Thall PF, Lee SJ, et al: Randomized multicenter phase II trial of two multicomponent regimens in androgen independent prostate cancer. J Clin Oncol 21:878-883, 2003
target: Reference
  l: https://pubmed.ncbi.nlm.nih.gov/12610188/
  reference:
    v: https://pubmed.ncbi.nlm.nih.gov/12610188/
  type:
    v: Citation
    l: Citation
  identifier:
    system:
      v: https://pubmed.ncbi.nlm.nih.gov
      l: pubmed.ncbi.nlm.nih.gov
    value:
      v: 12610188
    assigner:
      display:
        v: NLM

type:
  v: cites
classifier:
  coding:
    system:
      v: http://hl7.org/fhir/citation-artifact-classifier
      l: citation-artifact-classifier
    code:
      v: D016428
    display:
      v: Journal Article
citation:
  v: Petrylak DP, Tangen CM, Hussain MH, et al: Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 351:1513-1520, 2004
target: Reference
  l: https://pubmed.ncbi.nlm.nih.gov/15470214/
  reference:
    v: https://pubmed.ncbi.nlm.nih.gov/15470214/
  type:
    v: Citation
    l: Citation
  identifier:
    system:
      v: https://pubmed.ncbi.nlm.nih.gov
      l: pubmed.ncbi.nlm.nih.gov
    value:
      v: 15470214
    assigner:
      display:
        v: NLM

type:
  v: cites
classifier:
  coding:
    system:
      v: http://hl7.org/fhir/citation-artifact-classifier
      l: citation-artifact-classifier
    code:
      v: D016428
    display:
      v: Journal Article
citation:
  v: Tannock IF, de Wit R, Berry WR, et al: Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 351:1502-1512, 2004
target: Reference
  l: https://pubmed.ncbi.nlm.nih.gov/15470213/
  reference:
    v: https://pubmed.ncbi.nlm.nih.gov/15470213/
  type:
    v: Citation
    l: Citation
  identifier:
    system:
      v: https://pubmed.ncbi.nlm.nih.gov
      l: pubmed.ncbi.nlm.nih.gov
    value:
      v: 15470213
    assigner:
      display:
        v: NLM

type:
  v: cites
classifier:
  coding:
    system:
      v: http://hl7.org/fhir/citation-artifact-classifier
      l: citation-artifact-classifier
    code:
      v: D016428
    display:
      v: Journal Article
citation:
  v: Murphy GP, Beckley S, Brady MF, et al: Treatment of newly diagnosed metastatic prostate cancer patients with chemotherapy agents in combination with hormones versus hormones alone. Cancer 51:1264-1272, 1983
target: Reference
  l: https://pubmed.ncbi.nlm.nih.gov/6337697/
  reference:
    v: https://pubmed.ncbi.nlm.nih.gov/6337697/
  type:
    v: Citation
    l: Citation
  identifier:
    system:
      v: https://pubmed.ncbi.nlm.nih.gov
      l: pubmed.ncbi.nlm.nih.gov
    value:
      v: 6337697
    assigner:
      display:
        v: NLM

type:
  v: cites
classifier:
  coding:
    system:
      v: http://hl7.org/fhir/citation-artifact-classifier
      l: citation-artifact-classifier
    code:
      v: D016428
    display:
      v: Journal Article
citation:
  v: Murphy GP, Huben RP, Priore R: Results of another trial of chemotherapy with and without hormones in patients with newly diagnosed metastatic prostate cancer. Urology 28:36-40, 1986
target: Reference
  l: https://pubmed.ncbi.nlm.nih.gov/3523938/
  reference:
    v: https://pubmed.ncbi.nlm.nih.gov/3523938/
  type:
    v: Citation
    l: Citation
  identifier:
    system:
      v: https://pubmed.ncbi.nlm.nih.gov
      l: pubmed.ncbi.nlm.nih.gov
    value:
      v: 3523938
    assigner:
      display:
        v: NLM

type:
  v: cites
classifier:
  coding:
    system:
      v: http://hl7.org/fhir/citation-artifact-classifier
      l: citation-artifact-classifier
    code:
      v: D016428
    display:
      v: Journal Article
citation:
  v: Osborne CK, Blumenstein B, Crawford ED, et al: Combined versus sequential chemo-endocrine therapy in advanced prostate cancer: Final results of a randomized Southwest Oncology Group study. J Clin Oncol 8:1675-1682, 1990
target: Reference
  l: https://pubmed.ncbi.nlm.nih.gov/2213104/
  reference:
    v: https://pubmed.ncbi.nlm.nih.gov/2213104/
  type:
    v: Citation
    l: Citation
  identifier:
    system:
      v: https://pubmed.ncbi.nlm.nih.gov
      l: pubmed.ncbi.nlm.nih.gov
    value:
      v: 2213104
    assigner:
      display:
        v: NLM

type:
  v: cites
classifier:
  coding:
    system:
      v: http://hl7.org/fhir/citation-artifact-classifier
      l: citation-artifact-classifier
    code:
      v: D016428
    display:
      v: Journal Article
citation:
  v: Pummer K, Lehnert M, Stettner H, et al: Randomized comparison of total androgen blockade alone versus combined with weekly epirubicin in advanced prostate cancer. Eur Urol 32:81-85, 1997. (suppl)
target: Reference
  l: https://pubmed.ncbi.nlm.nih.gov/9267791/
  reference:
    v: https://pubmed.ncbi.nlm.nih.gov/9267791/
  type:
    v: Citation
    l: Citation
  identifier:
    system:
      v: https://pubmed.ncbi.nlm.nih.gov
      l: pubmed.ncbi.nlm.nih.gov
    value:
      v: 9267791
    assigner:
      display:
        v: NLM

type:
  v: cites
classifier:
  coding:
    system:
      v: http://hl7.org/fhir/citation-artifact-classifier
      l: citation-artifact-classifier
    code:
      v: D016428
    display:
      v: Journal Article
citation:
  v: Janknegt RA, Boon TA, van de Beek C, et al: Combined hormono/chemotherapy as primary treatment for metastatic prostate cancer: A randomized, multicenter study of orchiectomy alone versus orchiectomy plus estramustine phosphate. Urology 49:411-420, 1997
target: Reference
  l: https://pubmed.ncbi.nlm.nih.gov/9123707/
  reference:
    v: https://pubmed.ncbi.nlm.nih.gov/9123707/
  type:
    v: Citation
    l: Citation
  identifier:
    system:
      v: https://pubmed.ncbi.nlm.nih.gov
      l: pubmed.ncbi.nlm.nih.gov
    value:
      v: 9123707
    assigner:
      display:
        v: NLM

type:
  v: cites
classifier:
  coding:
    system:
      v: http://hl7.org/fhir/citation-artifact-classifier
      l: citation-artifact-classifier
    code:
      v: D016428
    display:
      v: Journal Article
citation:
  v: Fontana D, Bertetto O, Fasolis G, et al: Randomized comparison of goserelin acetate versus mitomycin C plus goserelin acetate in previously untreated prostate cancer patients with bone metastases. Tumori 84:39-44, 1998
target: Reference
  l: https://pubmed.ncbi.nlm.nih.gov/9619712/
  reference:
    v: https://pubmed.ncbi.nlm.nih.gov/9619712/
  type:
    v: Citation
    l: Citation
  identifier:
    system:
      v: https://pubmed.ncbi.nlm.nih.gov
      l: pubmed.ncbi.nlm.nih.gov
    value:
      v: 9619712
    assigner:
      display:
        v: NLM

type:
  v: cites
classifier:
  coding:
    system:
      v: http://hl7.org/fhir/citation-artifact-classifier
      l: citation-artifact-classifier
    code:
      v: D016428
    display:
      v: Journal Article
citation:
  v: Boel K, Van Poppel H, Goethuys H, et al: Mitomycin C for metastatic prostate cancer: Final analysis of a randomized trial. Anticancer Res 19:2157-2161, 1999
target: Reference
  l: https://pubmed.ncbi.nlm.nih.gov/10472324/
  reference:
    v: https://pubmed.ncbi.nlm.nih.gov/10472324/
  type:
    v: Citation
    l: Citation
  identifier:
    system:
      v: https://pubmed.ncbi.nlm.nih.gov
      l: pubmed.ncbi.nlm.nih.gov
    value:
      v: 10472324
    assigner:
      display:
        v: NLM

type:
  v: cites
classifier:
  coding:
    system:
      v: http://hl7.org/fhir/citation-artifact-classifier
      l: citation-artifact-classifier
    code:
      v: D016428
    display:
      v: Journal Article
citation:
  v: de Reijke TM, Keuppens FI, Whelan P, et al: Orchiectomy and orchiectomy plus mitomycin C for metastatic prostate cancer in patients with poor prognosis: The final results of a European organization for research in cancer therapy genitourinary group trial. J Urol 162:1658-1664, 1999
target: Reference
  l: https://pubmed.ncbi.nlm.nih.gov/10524892/
  reference:
    v: https://pubmed.ncbi.nlm.nih.gov/10524892/
  type:
    v: Citation
    l: Citation
  identifier:
    system:
      v: https://pubmed.ncbi.nlm.nih.gov
      l: pubmed.ncbi.nlm.nih.gov
    value:
      v: 10524892
    assigner:
      display:
        v: NLM

type:
  v: cites
classifier:
  coding:
    system:
      v: http://hl7.org/fhir/citation-artifact-classifier
      l: citation-artifact-classifier
    code:
      v: D016428
    display:
      v: Journal Article
citation:
  v: Kuriyama M, Takanhashi Y, Sahashi M, et al: Prospective and randomized comparison of combined androgen blockade versus combination with oral UFT as an initial treatment for prostate cancer. Jpn J Clin Oncol 31:18-24, 2001
target: Reference
  l: https://pubmed.ncbi.nlm.nih.gov/11256836/
  reference:
    v: https://pubmed.ncbi.nlm.nih.gov/11256836/
  type:
    v: Citation
    l: Citation
  identifier:
    system:
      v: https://pubmed.ncbi.nlm.nih.gov
      l: pubmed.ncbi.nlm.nih.gov
    value:
      v: 11256836
    assigner:
      display:
        v: NLM

type:
  v: cites
classifier:
  coding:
    system:
      v: http://hl7.org/fhir/citation-artifact-classifier
      l: citation-artifact-classifier
    code:
      v: D016428
    display:
      v: Journal Article
citation:
  v: Noguchi M, Noda Shinshi, Yoshida M, et al: Chemohormonal therapy as primary treatment for metastatic prostate cancer: A randomized study of estramustine phosphate plus luteinizing hormone-releasing hormone agonist versus flutamide plus luteinizing hormone-releasing hormone agonist. Int J Urol 11:103-109, 2004
target: Reference
  l: https://pubmed.ncbi.nlm.nih.gov/14706014/
  reference:
    v: https://pubmed.ncbi.nlm.nih.gov/14706014/
  type:
    v: Citation
    l: Citation
  identifier:
    system:
      v: https://pubmed.ncbi.nlm.nih.gov
      l: pubmed.ncbi.nlm.nih.gov
    value:
      v: 14706014
    assigner:
      display:
        v: NLM

type:
  v: cites
citation:
  v: Fisher LD, Belle GV: Biostatistics: A Methodology For the Health Sciences. New York, NY, John Wiley, 1993

type:
  v: cites
citation:
  v: Randles RH, Wolfe DA: Introduction to the Theory of Nonparametric Statistics. New York, NY, John Wiley, 1979

type:
  v: cites
citation:
  v: Lawless JF: Statistical Models and Methods for Lifetime Data. New York, NY, John Wiley, 1982

type:
  v: cites
classifier:
  coding:
    system:
      v: http://hl7.org/fhir/citation-artifact-classifier
      l: citation-artifact-classifier
    code:
      v: D016428
    display:
      v: Journal Article
citation:
  v: Hussain M, Tangen CM, Higano C, et al: Absolute prostate-specific antigen value after androgen deprivation is a strong independent predictor of survival in new metastatic prostate cancer: Data from the Southwest Oncology Group trial 9346 (INT-0162). J Clin Oncol 24:3984-3990, 2006
target: Reference
  l: https://pubmed.ncbi.nlm.nih.gov/16921051/
  reference:
    v: https://pubmed.ncbi.nlm.nih.gov/16921051/
  type:
    v: Citation
    l: Citation
  identifier:
    system:
      v: https://pubmed.ncbi.nlm.nih.gov
      l: pubmed.ncbi.nlm.nih.gov
    value:
      v: 16921051
    assigner:
      display:
        v: NLM

type:
  v: cites
classifier:
  coding:
    system:
      v: http://hl7.org/fhir/citation-artifact-classifier
      l: citation-artifact-classifier
    code:
      v: D016428
    display:
      v: Journal Article
citation:
  v: Stewart AJ, Scher HI, Chen M-H, et al: Prostate-specific antigen nadir and cancer-specific mortality following hormonal therapy for prostate-specific antigen failure. J Clin Oncol 23:6556-6560, 2005
target: Reference
  l: https://pubmed.ncbi.nlm.nih.gov/16170163/
  reference:
    v: https://pubmed.ncbi.nlm.nih.gov/16170163/
  type:
    v: Citation
    l: Citation
  identifier:
    system:
      v: https://pubmed.ncbi.nlm.nih.gov
      l: pubmed.ncbi.nlm.nih.gov
    value:
      v: 16170163
    assigner:
      display:
        v: NLM

type:
  v: cites
classifier:
  coding:
    system:
      v: http://hl7.org/fhir/citation-artifact-classifier
      l: citation-artifact-classifier
    code:
      v: D016428
    display:
      v: Journal Article
citation:
  v: Pettaway CA, Pisters LL, Troncoso P, et al: Neoadjuvant chemotherapy and hormonal therapy followed by radical prostatectomy: Feasibility and preliminary results. J Clin Oncol 18:1050-1057, 2000
target: Reference
  l: https://pubmed.ncbi.nlm.nih.gov/10694556/
  reference:
    v: https://pubmed.ncbi.nlm.nih.gov/10694556/
  type:
    v: Citation
    l: Citation
  identifier:
    system:
      v: https://pubmed.ncbi.nlm.nih.gov
      l: pubmed.ncbi.nlm.nih.gov
    value:
      v: 10694556
    assigner:
      display:
        v: NLM

type:
  v: cites
classifier:
  coding:
    system:
      v: http://hl7.org/fhir/citation-artifact-classifier
      l: citation-artifact-classifier
    code:
      v: D016428
    display:
      v: Journal Article
citation:
  v: Friedman J, Dunn RL, Wood D, et al: Neoadjuvant docetaxel and capecitabine in patients with high risk prostate cancer. J Urol 179:911-916, 2008
target: Reference
  l: https://pubmed.ncbi.nlm.nih.gov/18207190/
  reference:
    v: https://pubmed.ncbi.nlm.nih.gov/18207190/
  type:
    v: Citation
    l: Citation
  identifier:
    system:
      v: https://pubmed.ncbi.nlm.nih.gov
      l: pubmed.ncbi.nlm.nih.gov
    value:
      v: 18207190
    assigner:
      display:
        v: NLM

published in:
  type:
    coding:
      system:
        v: http://terminology.hl7.org/CodeSystem/published-in-type
        l: published-in-type
      code:
        v: D020492
      display:
        v: Periodical
  identifier:
    type:
      text:
        v: Electronic ISSN Type
    system:
      v: https://portal.issn.org
      l: portal.issn.org
    value:
      v: 1527-7755
  identifier:
    type:
      text:
        v: ISOAbbreviation
    system:
      v: https://www.issn.org/services/online-services/access-to-the-ltwa/
      l: access-to-the-ltwa
    value:
      v: J Clin Oncol
  identifier:
    type:
      text:
        v: ISSN Linking
    system:
      v: https://www.issn.org/understanding-the-issn/assignment-rules/the-issn-l-for-publications-on-multiple-media/
      l: the-issn-l-for-publications-on-multiple-media
    value:
      v: 0732-183X
  identifier:
    type:
      text:
        v: Medline Title Abbreviation
    system:
      v: https://www.nlm.nih.gov/tsd/cataloging/contructitleabbre.html
      l: contructitleabbre.html
    value:
      v: J Clin Oncol
  identifier:
    type:
      text:
        v: NLM Unique ID
    system:
      v: https://locatorplus.gov/cgi-bin/Pwebrecon.cgi
      l: https://locatorplus.gov/cgi-bin/Pwebrecon.cgi
    value:
      v: 8309333
  title:
    v: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  publisher location:
    v: United States
cited medium:
  coding:
    system:
      v: http://terminology.hl7.org/CodeSystem/cited-medium
      l: cited-medium
    code:
      v: internet
    display:
      v: Internet
volume:
  v: 26
issue:
  v: 36
article date:
  v: 2008-12-20
page string:
  v: 5936-42

v: Electronic

v: Electronic

v: XX

v: Organization identifier

v: XX

v: Organization identifier

v: XX

v: Organization identifier

v: XX

v: Organization identifier

cited medium:
  coding:
    system:
      v: http://terminology.hl7.org/CodeSystem/cited-medium
      l: cited-medium
    code:
      v: internet-without-issue
    display:
      v: Internet without issue
article date:
  v: 2008-11-24

classifier:
  coding:
    system:
      v: http://terminology.hl7.org/CodeSystem/artifact-url-classifier
      l: artifact-url-classifier
    code:
      v: abstract
    display:
      v: Abstract
url:
  v: https://pubmed.ncbi.nlm.nih.gov/19029421/
  l: https://pubmed.ncbi.nlm.nih.gov/19029421/

classifier:
  coding:
    system:
      v: http://terminology.hl7.org/CodeSystem/artifact-url-classifier
      l: artifact-url-classifier
    code:
      v: doi-based
    display:
      v: DOI Based
url:
  v: https://doi.org/10.1200/JCO.2007.15.9830
  l: JCO.2007.15.9830

type:
  coding:
    system:
      v: http://terminology.hl7.org/CodeSystem/cited-artifact-classification-type
      l: cited-artifact-classification-type
    code:
      v: publishing-model
    display:
      v: Publishing Model
    user selected:
      v: false
classifier:
  coding:
    system:
      v: http://terminology.hl7.org/CodeSystem/citation-artifact-classifier
      l: citation-artifact-classifier
    code:
      v: Print-Electronic
    display:
      v: Print Electronic
    user selected:
      v: false

type:
  coding:
    system:
      v: http://terminology.hl7.org/CodeSystem/cited-artifact-classification-type
      l: cited-artifact-classification-type
    code:
      v: chemical
    display:
      v: Chemical
    user selected:
      v: false
classifier:
  coding: D000726
    system:
      v: https://www.nlm.nih.gov/mesh
      l: mesh
    code:
      v: D000726
    display:
      v: Androgen Antagonists
    user selected:
      v: false
classifier:
  coding: D000903
    system:
      v: https://www.nlm.nih.gov/mesh
      l: mesh
    code:
      v: D000903
    display:
      v: Antibiotics, Antineoplastic
    user selected:
      v: false
classifier:
  coding: D018906
    system:
      v: https://www.nlm.nih.gov/mesh
      l: mesh
    code:
      v: D018906
    display:
      v: Antineoplastic Agents, Alkylating
    user selected:
      v: false
classifier:
  coding: D000972
    system:
      v: https://www.nlm.nih.gov/mesh
      l: mesh
    code:
      v: D000972
    display:
      v: Antineoplastic Agents, Phytogenic
    user selected:
      v: false
classifier:
  coding:
    system:
      v: https://www.cas.org/support/documentation/chemical-substances
      l: chemical-substances
    code:
      v: 35LT29625A
    user selected:
      v: false
  coding: D004961
    system:
      v: https://www.nlm.nih.gov/mesh
      l: mesh
    code:
      v: D004961
    display:
      v: Estramustine
    user selected:
      v: false
classifier:
  coding:
    system:
      v: https://www.cas.org/support/documentation/chemical-substances
      l: chemical-substances
    code:
      v: 5V9KLZ54CY
    user selected:
      v: false
  coding: D014747
    system:
      v: https://www.nlm.nih.gov/mesh
      l: mesh
    code:
      v: D014747
    display:
      v: Vinblastine
    user selected:
      v: false
classifier:
  coding:
    system:
      v: https://www.cas.org/support/documentation/chemical-substances
      l: chemical-substances
    code:
      v: 80168379AG
    user selected:
      v: false
  coding: D004317
    system:
      v: https://www.nlm.nih.gov/mesh
      l: mesh
    code:
      v: D004317
    display:
      v: Doxorubicin
    user selected:
      v: false
classifier:
  coding:
    system:
      v: https://www.cas.org/support/documentation/chemical-substances
      l: chemical-substances
    code:
      v: R9400W927I
    user selected:
      v: false
  coding: D007654
    system:
      v: https://www.nlm.nih.gov/mesh
      l: mesh
    code:
      v: D007654
    display:
      v: Ketoconazole
    user selected:
      v: false

type:
  coding:
    system:
      v: http://terminology.hl7.org/CodeSystem/cited-artifact-classification-type
      l: cited-artifact-classification-type
    code:
      v: mesh-heading
    display:
      v: MeSH heading
artifact assessment:
  l: meshHeading0
  reference:
    v: #meshHeading0
  type:
    v: ArtifactAssessment
    l: ArtifactAssessment

type:
  coding:
    system:
      v: http://terminology.hl7.org/CodeSystem/cited-artifact-classification-type
      l: cited-artifact-classification-type
    code:
      v: publication-type
    display:
      v: Publication type
classifier:
  coding: D017428
    system:
      v: https://www.nlm.nih.gov/mesh
      l: mesh
    code:
      v: D017428
    display:
      v: Clinical Trial, Phase III
    user selected:
      v: false
classifier:
  coding: D016428
    system:
      v: https://www.nlm.nih.gov/mesh
      l: mesh
    code:
      v: D016428
    display:
      v: Journal Article
    user selected:
      v: false
classifier:
  coding: D016449
    system:
      v: https://www.nlm.nih.gov/mesh
      l: mesh
    code:
      v: D016449
    display:
      v: Randomized Controlled Trial
    user selected:
      v: false

type:
  coding:
    system:
      v: http://terminology.hl7.org/CodeSystem/cited-artifact-classification-type
      l: cited-artifact-classification-type
    code:
      v: knowledge-artifact-type
    display:
      v: Knowledge Artifact Type
    user selected:
      v: false
classifier:
  coding:
    system:
      v: http://terminology.hl7.org/CodeSystem/citation-artifact-classifier
      l: citation-artifact-classifier
    code:
      v: D016428
    display:
      v: Journal Article
    user selected:
      v: false
artifact assessment:
  display:
    v: Classifier added by Computable Publishing LLC

type:
  coding:
    system:
      v: http://terminology.hl7.org/CodeSystem/cited-artifact-classification-type
      l: cited-artifact-classification-type
    code:
      v: citation-subset
    display:
      v: Citation subset
    user selected:
      v: false
classifier:
  coding:
    system:
      v: https://www.nlm.nih.gov/bsd/licensee/elements_descriptions.html#citationsubset
      l: citationsubset
    code:
      v: IM
    display:
      v: IM
    user selected:
      v: false

complete:
  v: true
entry:
  contributor:
    l: contributor0
    reference:
      v: #contributor0
    type:
      v: Practitioner
      l: Practitioner
    display:
      v: Millikan RE
  forename initials:
    v: RE
  affiliation:
    display:
      v: Department of Genitourinary Medical Oncology, University of Texas MD Anderson Cancer Center, 1155 Pressler, CPB7.3462, Houston, TX 77030, USA. rmillika@mdanderson.org
entry:
  contributor:
    l: contributor1
    reference:
      v: #contributor1
    type:
      v: Practitioner
      l: Practitioner
    display:
      v: Wen S
  forename initials:
    v: S
entry:
  contributor:
    l: contributor2
    reference:
      v: #contributor2
    type:
      v: Practitioner
      l: Practitioner
    display:
      v: Pagliaro LC
  forename initials:
    v: LC
entry:
  contributor:
    l: contributor3
    reference:
      v: #contributor3
    type:
      v: Practitioner
      l: Practitioner
    display:
      v: Brown MA
  forename initials:
    v: MA
entry:
  contributor:
    l: contributor4
    reference:
      v: #contributor4
    type:
      v: Practitioner
      l: Practitioner
    display:
      v: Moomey B
  forename initials:
    v: B
entry:
  contributor:
    l: contributor5
    reference:
      v: #contributor5
    type:
      v: Practitioner
      l: Practitioner
    display:
      v: Do KA
  forename initials:
    v: KA
entry:
  contributor:
    l: contributor6
    reference:
      v: #contributor6
    type:
      v: Practitioner
      l: Practitioner
    display:
      v: Logothetis CJ
  forename initials:
    v: CJ